Αρχική World News PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib... World News PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL Από Ogkologos - 17 Δεκεμβρίου, 2025 679 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR A Personalised Prediction Model Based on Clinical and Genomic Data Outperforms... 2 Σεπτεμβρίου, 2021 ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO... 4 Ιουλίου, 2025 Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine... 1 Μαρτίου, 2024 Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer? 20 Αυγούστου, 2024 Φόρτωση περισσοτέρων HOT NEWS Trial Produces Practice-Changing Findings for Some Children, Young Adults with Leukemia Brain Cancer Cells Hijack Gene “On Switches” to Drive Tumor Growth Patients With DCIS Reduce Risk Of Recurrence And Death If They... Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric...